IGA=Investigator’s Global Assessment.

^†A pooled analysis was performed on 1,366 rosacea subjects from 4 randomized controlled trials with IGA before and after treatment (ivermectin, metronidazole or vehicle). Assessments included the Dermatology Life Quality Index (DLQI) questionnaire and subject assessment of rosacea improvement. In one trial, success was defined as an investigator global assessment rating of ‘clear’ or ‘almost clear’ (IGA 0 or 1) following 16 weeks of treatment in subjects 18 years of age and older with ‘moderate’ to ‘severe’ papulopustular rosacea (IGA score of 3 or 4). Patients were followed after the treatment period to measure time to relapse (IGA score ≥2)¹

^‡The severity of rosacea is measured using a 5-point Investigator Global Assessment (IGA) scale in order to define the success of treatment. A final score of IGA 1 is ‘almost clear’ and IGA 0 is ‘clear’ of rosacea lesions and erythema. In interventional studies of rosacea, being ‘almost clear’ on IGA may be defined as success^3,4

References: 1. Webster G, et al. Defining treatment success in rosacea as ‘clear’ may provide multiple patient benefits: results of a pooled analysis. J Dermatolog Treat. 2017;28:469–474. 2. National Rosacea Society 2020. Rosacea review. Rosacea now estimated to affect at least 16 million American. Available at: https://www.rosacea.org/rosacea-review/2010/winter/rosacea-now-estimated-to-affect-at-least-16-million-americans. Accessed: May 2020.